Human Erythropoietin-alpha Recombinant

EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary endothelial and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epoin vivo. Non- glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activityin vitro.

A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/ml. This solution can then be diluted into other buffers.

The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C.  Upon reconstitution, store in working aliquots at 2 - 8° C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein.  Avoid repeated freeze/thaw cycles.